← Back to Search

Other

Novel Spectacle Lenses for Near-sightedness (CYPRESS Trial)

N/A

Waitlist Available

Research Sponsored by SightGlass Vision, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months

Awards & highlights

CYPRESS Trial Summary

This trial will test the safety and efficacy of a new spectacle lens design in reducing the progression of juvenile myopia (nearsightedness). The trial will last 36 months and will include three groups of participants.

Who is the study for?

This trial is for children aged 6-10 with near-sightedness, having a specific range of short-sighted prescription (-0.75 to -4.50 D). They must not have more than a 1.50 D difference between their eyes and be willing to participate for 3 years without wearing contact lenses.Check my eligibility

What is being tested?

The study tests new spectacle lens designs meant to slow down the worsening of near-sightedness in kids. It's a masked, three-group comparison lasting for three years where neither participants nor observers know who gets which type of glasses.See study design

What are the potential side effects?

Since this trial involves wearing special glasses, side effects are minimal but may include discomfort with fit or vision changes as the child adapts to the new lens design.

CYPRESS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Axial length

Spherical equivalent refraction

CYPRESS Trial Design

3Treatment groups

Experimental Treatment

Group I: Test Arm 3Experimental Treatment1 Intervention

Single vision, impact-resistant spectacle lenses

Group II: Test Arm 2Experimental Treatment1 Intervention

Single vision, impact-resistant spectacle lenses

Group III: Test Arm 1Experimental Treatment1 Intervention

Single vision, impact-resistant spectacle lenses

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Spectacle lenses

2022

N/A

~80

Novel spectacle lens design

2022

N/A

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

SightGlass Vision, Inc.Lead Sponsor

10 Previous Clinical Trials

827 Total Patients Enrolled

Joseph Rappon, OD, MS, FAAOStudy ChairSightGlass Vision, Inc.

1 Previous Clinical Trials

50 Total Patients Enrolled

Media Library

Novel spectacle lens design (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03623074 — N/A

Myopia or Nearsightedness Research Study Groups: Test Arm 3, Test Arm 2, Test Arm 1

Myopia or Nearsightedness Clinical Trial 2023: Novel spectacle lens design Highlights & Side Effects. Trial Name: NCT03623074 — N/A

Novel spectacle lens design (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03623074 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to partake in this medical study?

"To be eligible for the medical trial, participants must have myopia and fall between 6 to 10 years of age. At present, approximately 266 candidates are in the process of being recruited."

Answered by AI

How many health care facilities are currently running this experimental study?

"14 clinical trial locations are currently running this study, such as Eye Associates of Northeast Louisiana (DBA Haik Humble Eye Center) Research Dept in West Monroe, Visual Performance Center in Pensacola, and University of Houston College of Optometry in Houston. Additional sites can be found across the United States."

Answered by AI

Is the enrollment phase of this clinical trial still open?

"As per clinicaltrials.gov, this trial is not currently seeking participants. The study was initially posted on the 16th of July 2018 but has since been revamped on September 28th 2022. Though no longer open for participation, there are 98 other trials recruiting individuals at present."

Answered by AI